uPET SIGNED
Molecular imaging and targeted therapy of the aggressive phenotype: development of uPAR theranostics for cancer patients
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0uPET project word cloud
Explore the words cloud of the uPET project. It provides you a very rough idea of what is the project "uPET" about.
Project "uPET" data sheet
The following table provides information about the project.
| Coordinator |
REGION HOVEDSTADEN
Organization address contact info |
| Coordinator Country | Denmark [DK] |
| Total cost | 2˙072˙000 € |
| EC max contribution | 2˙072˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2014-ADG |
| Funding Scheme | ERC-ADG |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-10-01 to 2020-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | REGION HOVEDSTADEN | DK (HILLEROD) | coordinator | 2˙072˙000.00 |
Map
Project objective
For practice of personalized medicine in cancer, non-invasive tools for diagnosing at the molecular level are needed. Molecular imaging methods are capable of this while at the same time circumventing sampling error as the whole tumor burden is evaluated. We recently developed and performed the first-ever clinical PET scan of uPAR, a proteolytic system known to be strongly associated with metastatic potential in most cancer forms. We believe this new concept of uPAR-PET is a major breakthrough and has the potential to become one of the most used PET tracers as it fulfils unmet needs in prostate and breast cancer. Based on this, together with additional proof-of-concept data we obtained on targeting uPAR for optical imaging and radionuclide therapy, we now plan to develop and take into patients these new technologies for improved outcome. Specific aims are to develop and translate into human use: 1. A PET uPAR imaging ligand platform for visualization of the aggressive phenotype and risk-stratification to be used in tailoring therapy, e.g. in prostate cancer to decide whether prostatectomy is necessary. 2. uPAR-PET combined with simultaneous 13C-hyperpolarized pyruvate MRSI (Warburg effect). This will increase prognostic power, refine tumor phenotyping and thereby allow for better tailoring of therapy and early prediction of treatment response. 3. A uPAR optical imaging technology for guiding removal of cancer tissue during surgery. This will help delineate cancer tissue for removal while leaving healthy tissue behind. We expect better outcome with removal of less tissue. 4. Selective radionuclide therapies targeting uPAR positive, invasive cancer cells using β or α emitters. Dose planning will be performed using uPAR-PET imaging. This image-therapy pairing is also known as theranostics. Our endeavour is ambitious, yet realistic considering our competencies and track-record. We expect cancer patients to benefit from our new methods within the 5 year time-frame.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Adam E. Hansen, Henrik Gutte, Pernille Holst, Helle H. Johannesen, Sofie Rahbek, Andreas E. Clemmensen, Majbritt M.E. Larsen, Christina Schøier, Jan Ardenkjaer-Larsen, Thomas L. Klausen, Annemarie T. Kristensen, Andreas Kjaer Combined hyperpolarized 13 C-pyruvate MRS and 18 F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients published pages: 6-12, ISSN: 0720-048X, DOI: 10.1016/j.ejrad.2018.02.028 |
European Journal of Radiology 103 | 2019-07-05 |
| 2017 |
Christensen A, Juhl K, Persson M, Charabi BW, Mortensen J, Kiss K, Lelkaitis G, Rubek N, von Buchwald C, Kjær A uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.14282 |
Oncotarget | 2019-07-05 |
| 2017 |
Skovgaard D, Persson M, Brandt-Larsen M, Christensen C, Madsen J, Klausen TL, Holm S, Andersen FL, Loft A, Berthelsen AK, Pappot H, Brasso K, Kroman N, Højgaard L, Kjaer A Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging published pages: 379-386, ISSN: 2159-662X, DOI: 10.2967/jnumed.116.178970 |
J Nucl Med 58(3) | 2019-07-05 |
| 2016 |
Adam E. Hansen, Flemming L. Andersen, Sarah T. Henriksen, Alexandre Vignaud, Jan H. Ardenkjaer-Larsen, Liselotte Højgaard, Andreas Kjaer, Thomas L. Klausen Simultaneous PET/MRI with 13C magnetic resonance spectroscopic imaging (hyperPET): phantom-based evaluation of PET quantification published pages: 7 (13 pages), ISSN: 2197-7364, DOI: 10.1186/s40658-016-0143-6 |
EJNMMI Physics 3/1 | 2019-07-05 |
| 2017 |
Loft MD, Sun Y, Liu C, Christensen C, Huang D, Kjaer A, Cheng Z Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR) published pages: 1089-1100, ISSN: 1438-2199, DOI: 10.1007/s00726-017-2407-4 |
Amino Acids 49(6) | 2019-07-05 |
| 2018 |
Sorel Kurbegovic, Karina Juhl, Hao Chen, Chunrong Qu, Bingbing Ding, Julie Maja Leth, Krzysztof Tadeusz Drzewiecki, Andreas Kjaer, Zhen Cheng Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery published pages: 3833-3840, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00669 |
Bioconjugate Chemistry 29/11 | 2019-04-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UPET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "UPET" are provided by the European Opendata Portal: CORDIS opendata.